MX2014004679A - Preparacion de liberacion sostenida. - Google Patents

Preparacion de liberacion sostenida.

Info

Publication number
MX2014004679A
MX2014004679A MX2014004679A MX2014004679A MX2014004679A MX 2014004679 A MX2014004679 A MX 2014004679A MX 2014004679 A MX2014004679 A MX 2014004679A MX 2014004679 A MX2014004679 A MX 2014004679A MX 2014004679 A MX2014004679 A MX 2014004679A
Authority
MX
Mexico
Prior art keywords
sustained
release preparation
pioglitazone
salt
average
Prior art date
Application number
MX2014004679A
Other languages
English (en)
Inventor
Yutaka Tanoue
Yusuke Murakawa
Yumiko Ishii
Kaoru Takenaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014004679(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2014004679A publication Critical patent/MX2014004679A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una preparación de liberación sostenida que contiene pioglitazona o una sal de ésta como un ingrediente activo y que muestra superior sostenibilidad. Una preparación de liberación sostenida que contiene pioglitazona o una sal de ésta, que muestra una relación de disolución de pioglitazona de 25-58% promedio en el punto de tiempo de 2 horas, y 60-100% de promedio en el punto de tiempo de 4 horas, en una prueba de disolución de acuerdo con el método de paletas USP de 50 rpm y usando amortiguador de KCI/HCI pH 2,0 a 37°C como una solución de ensayo.
MX2014004679A 2011-10-21 2012-10-19 Preparacion de liberacion sostenida. MX2014004679A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21
PCT/JP2012/077662 WO2013058409A1 (en) 2011-10-21 2012-10-19 Sustained-release preparation

Publications (1)

Publication Number Publication Date
MX2014004679A true MX2014004679A (es) 2014-08-01

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004679A MX2014004679A (es) 2011-10-21 2012-10-19 Preparacion de liberacion sostenida.

Country Status (29)

Country Link
US (1) US9907789B2 (es)
EP (1) EP2768487B1 (es)
JP (1) JP6093762B2 (es)
KR (1) KR20140081826A (es)
CN (1) CN104039313A (es)
AP (1) AP2014007645A0 (es)
AR (1) AR088398A1 (es)
AU (1) AU2012326976B2 (es)
BR (1) BR112014008744A2 (es)
CA (1) CA2852417A1 (es)
CL (1) CL2014000992A1 (es)
CO (1) CO6960544A2 (es)
CR (1) CR20140213A (es)
DO (1) DOP2014000077A (es)
EA (1) EA201490840A1 (es)
EC (1) ECSP14013328A (es)
IL (1) IL232114A0 (es)
IN (1) IN2014DN03169A (es)
MA (1) MA35717B1 (es)
MX (1) MX2014004679A (es)
NZ (1) NZ624275A (es)
PE (1) PE20141189A1 (es)
SG (2) SG10201700121YA (es)
TN (1) TN2014000152A1 (es)
TW (1) TW201323018A (es)
UA (1) UA113858C2 (es)
UY (1) UY34403A (es)
WO (1) WO2013058409A1 (es)
ZA (1) ZA201403103B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013058409A1 (en) 2011-10-21 2013-04-25 Takeda Pharmaceutical Company Limited Sustained-release preparation
JP5911638B2 (ja) 2012-04-20 2016-04-27 ギリアード サイエンシーズ， インコーポレイテッド ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DK0661045T3 (da) 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
WO2003013609A1 (en) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
KR20100137023A (ko) 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
IN192749B (es) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
WO2004082665A1 (ja) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited 放出制御組成物
ZA200508932B (en) 2003-06-06 2007-03-28 Takeda Pharmaceutical Solid pharmaceutical preparation
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
CA2562391A1 (en) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
WO2006024949A2 (en) 2004-08-31 2006-03-09 Pfizer Products Inc. Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
KR20080058413A (ko) 2005-09-22 2008-06-25 에스비 팜코 푸에르토 리코 인크. Ａｐｏｅ4 음성 환자에서의 인지 기능의 개선을 위한ｐｐａｒ-감마 작동제
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
PE20110019A1 (es) 2005-12-22 2011-01-27 Takeda Pharmaceutical Composicion farmaceutica que contiene un sensibilizante de insulina y un secretagogo de insulina
PL2002828T3 (pl) 2006-03-30 2019-11-29 Nippon Zoki Pharmaceutical Co Stały preparat farmaceutyczny
PE20080696A1 (es) 2006-04-27 2008-08-04 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un derivado de bencimidazol y clorhidrato de pioglitazona
PL2120878T3 (pl) 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
AU2009298684B2 (en) 2008-09-30 2015-11-19 Konstantinos Ritis Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
CN101884627B (zh) * 2010-07-07 2012-01-25 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
MX355479B (es) * 2011-01-10 2018-04-19 Zinfandel Pharmaceuticals Inc Metodos y productos de farmaco para tratar enfermedad de alzheimer.
WO2013058409A1 (en) 2011-10-21 2013-04-25 Takeda Pharmaceutical Company Limited Sustained-release preparation
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Also Published As

Publication number Publication date
ZA201403103B (en) 2015-08-26
US20140248362A1 (en) 2014-09-04
AR088398A1 (es) 2014-05-28
CA2852417A1 (en) 2013-04-25
US9907789B2 (en) 2018-03-06
TN2014000152A1 (en) 2015-09-30
CN104039313A (zh) 2014-09-10
NZ624275A (en) 2016-09-30
UY34403A (es) 2013-05-31
EP2768487B1 (en) 2020-06-03
IL232114A0 (en) 2014-06-30
AU2012326976A2 (en) 2014-06-12
EP2768487A1 (en) 2014-08-27
MA35717B1 (fr) 2014-12-01
TW201323018A (zh) 2013-06-16
UA113858C2 (uk) 2017-03-27
PE20141189A1 (es) 2014-09-24
JP6093762B2 (ja) 2017-03-08
DOP2014000077A (es) 2014-07-15
CR20140213A (es) 2014-06-18
SG10201700121YA (en) 2017-03-30
WO2013058409A1 (en) 2013-04-25
CO6960544A2 (es) 2014-05-30
CL2014000992A1 (es) 2014-09-05
AP2014007645A0 (en) 2014-05-31
BR112014008744A2 (pt) 2017-04-18
IN2014DN03169A (es) 2015-05-22
SG2014012025A (en) 2014-06-27
KR20140081826A (ko) 2014-07-01
ECSP14013328A (es) 2014-05-31
EA201490840A1 (ru) 2014-08-29
JP2014530802A (ja) 2014-11-20
AU2012326976A1 (en) 2014-05-29
AU2012326976B2 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
NZ602685A (en) Concentrated protein formulations and uses thereof
TN2014000152A1 (en) Sustained-release preparation
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
EP2883932A3 (en) Aqueous solution and method for use thereof
MX358716B (es) Composiciones estables para el cuidado bucal que comprenden un aminoácido básico , una sal de estroncio y una fuente de ion fluoruro y usos de las mismas.
PH12016501175B1 (en) Formulations of deoxycholic acid and salts thereof
ZA201504284B (en) Solution for preserving vascular conduits
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
PH12017501397A1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
PH12016500909B1 (en) Solutons for increasing the stability and shelf life of an organ tissue preservation solution
MX2017010666A (es) Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico.
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
PH12014502407A1 (en) New alfentanil composition for the treatment of acute pain
EA201792122A1 (ru) Кристаллическое соединение как ингибитор фермента семикарбазидчувствительной аминоксидазы (ssao)
WO2012074237A3 (ko) 도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물
EA201390844A1 (ru) Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения
MY163015A (en) Dentifrice composition
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
UA110933C2 (uk) Композиція для лікування есенціальної тромбоцитемії
RS53612B1 (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING IBUPROFEN SALTS
TN2010000012A1 (en) Stable pharmaceutical composition of a water soluble vinorelbine salt
RU2010129784A (ru) Способ приготовления противотуберкулезного лекарственного препарата
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
WO2009155488A3 (en) Novel oxalate salt and crystal of o-desmethylvenlafaxine